| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2021 | PALM THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43NS122619 | A Small Molecule Enzyme Replacement for the Treatment of CLN1 | 000 | 1 | NIH | 12/11/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = -$97,798 ) |
| | 2024 | 2022 | PALM THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43CA250702 | Targeted Depalmitoylation for the Treatment of NRas-Driven Melanoma | 001 | 1 | NIH | 12/21/2023 | -$61,500 |
| | 2024 | 2021 | PALM THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43CA250702 | Targeted Depalmitoylation for the Treatment of NRas-Driven Melanoma | 000 | 1 | NIH | 12/21/2023 | -$36,298 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2021 | PALM THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43NS122619 | A Small Molecule Enzyme Replacement for the Treatment of CLN1 | 000 | 1 | NIH | 6/23/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $61,500 ) |
| | 2022 | 2022 | PALM THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43CA250702 | Targeted Depalmitoylation for the Treatment of NRas-Driven Melanoma | 002 | 1 | NIH | 8/30/2022 | $0 |
| | 2022 | 2022 | PALM THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43CA250702 | Targeted Depalmitoylation for the Treatment of NRas-Driven Melanoma | 000 | 1 | NIH | 3/21/2022 | $61,500 |
| | 2022 | 2020 | PALM THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43CA250702 | Targeted Depalmitoylation for the Treatment of NRas-Driven Melanoma | 001 | 1 | NIH | 8/30/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $590,813 ) |
| | 2021 | 2021 | PALM THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43CA250702 | Targeted Depalmitoylation for the Treatment of NRas-Driven Melanoma | 001 | 1 | NIH | 9/24/2021 | -$123,722 |
| | 2021 | 2021 | PALM THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43CA250702 | Targeted Depalmitoylation for the Treatment of NRas-Driven Melanoma | 001 | 1 | NIH | 9/24/2021 | $123,722 |
| | 2021 | 2021 | PALM THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43NS122619 | A Small Molecule Enzyme Replacement for the Treatment of CLN1 | 000 | 1 | NIH | 8/12/2021 | $402,852 |
| | 2021 | 2021 | PALM THERAPEUTICS, INC. | 3210 MERRYFIELD ROW | SAN DIEGO | CA | 92121-1126 | SAN DIEGO | USA | R43NS122619 | A Small Molecule Enzyme Replacement for the Treatment of CLN1 | 001 | 1 | NIH | 8/23/2021 | $64,239 |
| | 2021 | 2021 | PALM THERAPEUTICS, INC. | 8528 VIA MALLORCA UNIT F | LA JOLLA | CA | 92037-2515 | SAN DIEGO | USA | R43CA250702 | Targeted Depalmitoylation for the Treatment of NRas-Driven Melanoma | 000 | 1 | NIH | 6/4/2021 | $123,722 |
|
| Issue Date FY: 2020 ( Subtotal = $399,888 ) |
| | 2020 | 2020 | PALM THERAPEUTICS, INC. | 8528 VIA MALLORCA UNIT F | LA JOLLA | CA | 92037-2515 | SAN DIEGO | USA | R43CA250702 | Targeted Depalmitoylation for the Treatment of NRas-Driven Melanoma | 000 | 1 | NIH | 9/21/2020 | $399,888 |
|
|
